{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer+Metastases",
    "query": {
      "condition": "Breast Cancer Metastases"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 692,
    "total_pages": 70,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer+Metastases&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-10T18:50:00.562Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00626106",
      "title": "QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Tumors",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "AMG 479",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NantCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 156,
      "start_date": "2008-03-27",
      "completion_date": "2011-09-23",
      "has_results": true,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 25,
      "location_summary": "Chandler, Arizona • Anaheim, California • Beverly Hills, California + 22 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Concord",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00626106"
    },
    {
      "nct_id": "NCT03742349",
      "title": "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Triple Negative Breast Cancer (TNBC)"
      ],
      "interventions": [
        {
          "name": "spartalizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "LAG525",
          "type": "BIOLOGICAL"
        },
        {
          "name": "NIR178",
          "type": "DRUG"
        },
        {
          "name": "capmatinib",
          "type": "DRUG"
        },
        {
          "name": "MCS110",
          "type": "BIOLOGICAL"
        },
        {
          "name": "canakinumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2019-01-31",
      "completion_date": "2023-02-06",
      "has_results": false,
      "last_update_posted_date": "2025-05-18",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 2,
      "location_summary": "New York, New York • Nashville, Tennessee",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03742349"
    },
    {
      "nct_id": "NCT03038152",
      "title": "Magseed Magnetic Marker in Locating Axillary Lymph Nodes in Patients With Breast Cancer Undergoing Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Breast Carcinoma Metastatic in Lymph Node",
        "Stage II Breast Cancer AJCC v6 and v7",
        "Stage IIA Breast Cancer AJCC v6 and v7",
        "Stage IIB Breast Cancer AJCC v6 and v7",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Axillary Lymph Node Dissection",
          "type": "PROCEDURE"
        },
        {
          "name": "Localization",
          "type": "PROCEDURE"
        },
        {
          "name": "Medical Device",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DEVICE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2017-04-11",
      "completion_date": "2021-03-01",
      "has_results": false,
      "last_update_posted_date": "2021-03-05",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038152"
    },
    {
      "nct_id": "NCT00083733",
      "title": "Genetic and Protein Profiling in Normal and Cancerous Breast Tissue",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 216,
      "start_date": "2004-05-27",
      "completion_date": "2010-11-17",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00083733"
    },
    {
      "nct_id": "NCT02274623",
      "title": "Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Prostate Cancer",
        "Bone Neoplasms",
        "Hypocalcemia",
        "Hyperparathyroidism, Secondary"
      ],
      "interventions": [
        {
          "name": "CTAP101 Capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OPKO Health, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2014-12",
      "completion_date": "2017-03-17",
      "has_results": false,
      "last_update_posted_date": "2019-09-27",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 6,
      "location_summary": "Long Beach, California • Miami, Florida • Evergreen Park, Illinois + 3 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Evergreen Park",
          "state": "Illinois"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02274623"
    },
    {
      "nct_id": "NCT01602380",
      "title": "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hormone Receptor Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "faslodex 500mg",
          "type": "DRUG"
        },
        {
          "name": "arimidex 1mg",
          "type": "DRUG"
        },
        {
          "name": "faslodex dummy",
          "type": "DRUG"
        },
        {
          "name": "arimidex dummy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 462,
      "start_date": "2012-10-17",
      "completion_date": "2026-01-16",
      "has_results": true,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 12,
      "location_summary": "Modesto, California • Savannah, Georgia • Auburn, Maine + 9 more",
      "locations": [
        {
          "city": "Modesto",
          "state": "California"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Auburn",
          "state": "Maine"
        },
        {
          "city": "Worcester",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01602380"
    },
    {
      "nct_id": "NCT04991480",
      "title": "A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ART4215",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Artios Pharma Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2021-09-13",
      "completion_date": "2025-12-24",
      "has_results": false,
      "last_update_posted_date": "2026-01-27",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 7,
      "location_summary": "New Haven, Connecticut • Orlando, Florida • New York, New York + 4 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04991480"
    },
    {
      "nct_id": "NCT01572727",
      "title": "A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "BKM120 matching placebo",
          "type": "DRUG"
        },
        {
          "name": "BKM120",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 416,
      "start_date": "2012-08",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2017-03-09",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 21,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Fayetteville, Arkansas + 17 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Greenwood Village",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01572727"
    },
    {
      "nct_id": "NCT01305941",
      "title": "A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HER-2 Positive Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Vinorelbine",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2011-09",
      "completion_date": "2017-10-16",
      "has_results": true,
      "last_update_posted_date": "2018-12-17",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 4,
      "location_summary": "Birmingham, Alabama • Chapel Hill, North Carolina • Charlotte, North Carolina + 1 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01305941"
    },
    {
      "nct_id": "NCT04947917",
      "title": "Axillary Lymph Node Tattoo Marking Study",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Lymph Node Metastases"
      ],
      "interventions": [
        {
          "name": "SpotTM Tattoo Ink",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2021-12-29",
      "completion_date": "2023-04-13",
      "has_results": false,
      "last_update_posted_date": "2024-01-23",
      "last_synced_at": "2026-09-10T18:50:00.562Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04947917"
    }
  ]
}